INBX vs ABBV vs PFE vs BMY vs REGN

For growth investors, Inhibrx Biosciences, Inc.

(INBX) is the stronger pick with 550. 0% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus AbbVie Inc. at 85. 5x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x.

Over the past 5 years, Inhibrx Biosciences, Inc.

(INBX) delivered a total return of +694. 0%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: INBX returned +507. 7% versus BMY's +6. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Inhibrx Biosciences, Inc. 's 1. 79β — meaning INBX is approximately 430% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 13% for Inhibrx Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Inhibrx Biosciences, Inc.

(INBX) is pulling ahead at 550. 0% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -107. 8% for Inhibrx Biosciences, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -107. 7% for Inhibrx Biosciences, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -103. 9% for INBX. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.

9x forward P/E versus 15. 3x for Regeneron Pharmaceuticals, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 26. 6% to $256. 64.

In this comparison, PFE (6.

5% yield), BMY (4. 4% yield), ABBV (3. 2% yield), REGN (0. 5% yield) pay a dividend. INBX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Inhibrx Biosciences, Inc. (INBX) carries a higher beta of 1. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, INBX: +507. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INBX is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; PFE is a mid-cap income-oriented stock; BMY is a mid-cap deep-value stock; REGN is a mid-cap deep-value stock. ABBV, PFE, BMY pay a dividend while INBX, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.